Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

By E. Simpson, T. Bieber, E. Guttman‐Yassky, L. Beck, A. Blauvelt, M. Cork, J. Silverberg, M. Deleuran, Y. Kataoka, J. Lacour and 15 more. New England Journal of Medicine, 2016

1,730 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/15c04fb27789965d9f7ebb8fc45ac4e4be0ae0c3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Hsieh
2. Alexander Y. Rudensky

In Physiology

1. R. Gereau

Citations in the corpus

• Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch (2017, positive): “Notably, dupilumab, a recently approved monoclonal antibody that blocks both IL-4 and IL-13 signaling via their shared receptor subunit IL-4Ra, has demonstrated remarkable efficacy in treating AD (Beck et al., 2014; Simpson et al., 2016; Thaçi et al., 2016).”